GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (OTCPK:KYRNF) » Definitions » Gross-Profit-to-Asset %

Kyorin Pharmaceutical Co (Kyorin Pharmaceutical Co) Gross-Profit-to-Asset % : 33.48% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Kyorin Pharmaceutical Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Kyorin Pharmaceutical Co's annualized Gross Profit for the quarter that ended in Dec. 2023 was $407.5 Mil. Kyorin Pharmaceutical Co's average Total Assets over the quarter that ended in Dec. 2023 was $1,217.2 Mil. Therefore, Kyorin Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 33.48%.


Kyorin Pharmaceutical Co Gross-Profit-to-Asset % Historical Data

The historical data trend for Kyorin Pharmaceutical Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co Gross-Profit-to-Asset % Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.67 30.38 27.91 27.13 27.42

Kyorin Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.06 27.28 25.60 33.48 28.79

Competitive Comparison of Kyorin Pharmaceutical Co's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Gross-Profit-to-Asset % falls into.



Kyorin Pharmaceutical Co Gross-Profit-to-Asset % Calculation

Kyorin Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Mar. 2024 )/( (Total Assets (A: Mar. 2023 )+Total Assets (A: Mar. 2024 ))/ count )
=343.135/( (1317.068+1185.961)/ 2 )
=343.135/1251.5145
=27.42 %

Kyorin Pharmaceutical Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=407.524/( (1191.62+1242.812)/ 2 )
=407.524/1217.216
=33.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Kyorin Pharmaceutical Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyorin Pharmaceutical Co (Kyorin Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (Kyorin Pharmaceutical Co) Headlines

No Headlines